Pfizer and Glenmark Pharmaceuticals have joined hands to launch abrocitinib, an oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
When launched in India, it will be co-marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively.
Abrocitinib (CIBINQO) is available in over 35 markets globally, including the US, Japan, and China.
Atopic dermatitis is a chronic skin disease characterised by inflammation of the skin and skin barrier defects. The persistent itching associated with moderate-to-severe AD disrupts daily life, impacting social interactions, work productivity, and overall well-being. Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, provides rapid itch relief, sustained disease control, and a vastly improved quality of life for patients.